Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye injection targets two causes of vision loss in wet AMD

NCT ID NCT05456828

Disease control Sponsor: Visara, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a new drug called ASKG712 in 56 people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The drug is injected into the eye and works by blocking two proteins that fuel abnormal blood vessel growth. The main goals were to check safety and how the drug moves through the body, with some early looks at vision outcomes. The trial has been completed, but results are not yet public.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ASKG712 (a protein that blocks two growth factors involved in abnormal blood vessel growth in the eye)
What this could lead to
If successful, this could lead to a new treatment option for wet age-related macular degeneration that targets two pathways at once, potentially offering better or longer-lasting vision protection.
What could go wrong
This is an early Phase 1/2a study with only 56 participants, so safety and effectiveness are not yet proven. The treatment is injected directly into the eye, which carries risks like infection or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

56 people

The number who actually took part.

Started

Feb 2023

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Signed the informed consent form; * 2\. Male or female subjects with 50\~80 years of age; * 3\. Active sub-foveal or juxta-foveal choroidal neovascularization (CNV) lesions secondary to neovascular age-related macular degeneration (nAMD); * 4\. Total lesion area ≤ 12 disc area (DA); * 5\. BCVA letter score measured at screening of 19\~78 letters. Exclusion Criteria: * 1\. History of uveitis in either eye； * 2\. Current active inflammation or infection in the study eye; * 3\. Central foveal scar, fibrosis or atrophy of macular in the study eye; * 4\. Subretinal hemorrhage area in the study eye ≥ 50% of total lesion size; * 5\. Scar or fibrosis area in study eyes ≥ 50% of total lesion size; * 6\. History or any concurrent ocular condition which, in the opinion of the investigator, could either confound interpretation of efficacy and safety of ASKG712 or require medical or surgical intervention. * 7\. Presence of retinal pigment epithelial tear; * 8\. Previous intraocular operations in the study eye; * 9\. Uncontrolled previous or current glaucoma in either eye, or previous glaucoma filtering operation in the study eye; * 10\. Previous anti-VEGF drug treatment within 60 days prior to screening； * 11\. Diseases that affect intravenous injection and venous blood sampling; * 12\. Systemic autoimmune diseases; * 13\. Any uncontrolled clinical disorders; * 14\. History of allergy or current allergic response to ASKG712 or fluorescein; * 15\. Pregnant or nursing women; * 16\. Subjects should be excluded in the opinion of investigators.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neovascular age-related macular degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neovascular age-related macular degeneration

Contacts and locations

Locations

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.